Biology:NAB2

From HandWiki
Revision as of 05:58, 12 February 2024 by Ohm (talk | contribs) (add)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Protein-coding gene in the species Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

NGFI-A-binding protein 2 also known as EGR-1-binding protein 2 or melanoma-associated delayed early response protein (MADER) is a protein that in humans is encoded by the NAB2 gene.[1][2][3]

Function

This gene encodes a member of the family of NGFI-A binding (NAB) proteins, which function in the nucleus to repress or activate transcription induced by some members of the EGR (early growth response) family of transactivators. NAB proteins can homo- or hetero-multimerize with other EGR or NAB proteins through a conserved N-terminal domain, and repress transcription through two partially redundant C-terminal domains. Transcriptional repression by the encoded protein is mediated in part by interactions with the nucleosome remodeling and deactylase (NuRD) complex. Alternatively spliced transcript variants have been described, but their biological validity has not been determined.[3]

Pathology

Recurrent somatic fusions of the two genes, NGFI-A–binding protein 2 (NAB2) and STAT6, located at chromosomal region 12q13, have been identified in solitary fibrous tumors.[4]

References

  1. "NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli". Mol Cell Biol 16 (7): 3545–53. Aug 1996. doi:10.1128/MCB.16.7.3545. PMID 8668170. 
  2. "Mader: a novel nuclear protein over expressed in human melanomas". Oncogene 12 (5): 963–71. Jul 1996. PMID 8649813. 
  3. 3.0 3.1 "Entrez Gene: NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2)". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4665. 
  4. Kabbinavar, F. F.; Hambleton, J; Mass, R. D.; Hurwitz, H. I.; Bergsland, E; Sarkar, S (2005). "Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer". Journal of Clinical Oncology 23 (16): 3706–12. doi:10.1200/JCO.2005.00.232. PMID 15867200. 

Further reading